Cargando…

Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation

Lung cancer has been the leading cause of cancer-related deaths in both developed and developing countries, with most primary lung cancers being non-small cell lung carcinomas. Treatment for this condition is sometimes individualized. With developments in modern treatment and phase III clinical tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Thai Hoa Thi, Pham, Xuan Dung, Dao, Khanh Linh, Vo, Thanh Toan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299391/
https://www.ncbi.nlm.nih.gov/pubmed/34326746
http://dx.doi.org/10.1159/000516404
_version_ 1783726260774502400
author Nguyen, Thai Hoa Thi
Pham, Xuan Dung
Dao, Khanh Linh
Vo, Thanh Toan
author_facet Nguyen, Thai Hoa Thi
Pham, Xuan Dung
Dao, Khanh Linh
Vo, Thanh Toan
author_sort Nguyen, Thai Hoa Thi
collection PubMed
description Lung cancer has been the leading cause of cancer-related deaths in both developed and developing countries, with most primary lung cancers being non-small cell lung carcinomas. Treatment for this condition is sometimes individualized. With developments in modern treatment and phase III clinical trial results, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) and ALK-TKI have proven thier superior effectivity in comparison with the standard platinum-based doublet and are commonly approved as first-line indications in previously untreated advanced non-small cell lung cancer (NSCLC) patients with EGFR or ALK mutations. In the majority of cases, the presence of the ALK rearrangement mutation does not overlap with other mutations in NSCLC. Here, we report a patient with concomitant ALK rearrangement and EGFR mutation treated with a combination of TKIs: osimertinib and ceritinib.
format Online
Article
Text
id pubmed-8299391
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-82993912021-07-28 Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation Nguyen, Thai Hoa Thi Pham, Xuan Dung Dao, Khanh Linh Vo, Thanh Toan Case Rep Oncol Case Report Lung cancer has been the leading cause of cancer-related deaths in both developed and developing countries, with most primary lung cancers being non-small cell lung carcinomas. Treatment for this condition is sometimes individualized. With developments in modern treatment and phase III clinical trial results, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) and ALK-TKI have proven thier superior effectivity in comparison with the standard platinum-based doublet and are commonly approved as first-line indications in previously untreated advanced non-small cell lung cancer (NSCLC) patients with EGFR or ALK mutations. In the majority of cases, the presence of the ALK rearrangement mutation does not overlap with other mutations in NSCLC. Here, we report a patient with concomitant ALK rearrangement and EGFR mutation treated with a combination of TKIs: osimertinib and ceritinib. S. Karger AG 2021-07-08 /pmc/articles/PMC8299391/ /pubmed/34326746 http://dx.doi.org/10.1159/000516404 Text en Copyright © 2021 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Nguyen, Thai Hoa Thi
Pham, Xuan Dung
Dao, Khanh Linh
Vo, Thanh Toan
Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation
title Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation
title_full Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation
title_fullStr Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation
title_full_unstemmed Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation
title_short Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation
title_sort response to a combination of full-dose osimertinib and ceritinib in a non-small cell lung cancer patient with eml4-alk rearrangement and epidermal growth factor receptor co-mutation
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299391/
https://www.ncbi.nlm.nih.gov/pubmed/34326746
http://dx.doi.org/10.1159/000516404
work_keys_str_mv AT nguyenthaihoathi responsetoacombinationoffulldoseosimertinibandceritinibinanonsmallcelllungcancerpatientwitheml4alkrearrangementandepidermalgrowthfactorreceptorcomutation
AT phamxuandung responsetoacombinationoffulldoseosimertinibandceritinibinanonsmallcelllungcancerpatientwitheml4alkrearrangementandepidermalgrowthfactorreceptorcomutation
AT daokhanhlinh responsetoacombinationoffulldoseosimertinibandceritinibinanonsmallcelllungcancerpatientwitheml4alkrearrangementandepidermalgrowthfactorreceptorcomutation
AT vothanhtoan responsetoacombinationoffulldoseosimertinibandceritinibinanonsmallcelllungcancerpatientwitheml4alkrearrangementandepidermalgrowthfactorreceptorcomutation